Patient Blood Management in the Approach to Prosthetic Surgery in Orthopedic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anemia, Iron Deficiency
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Enrollment
- 142
- Locations
- 1
- Primary Endpoint
- Reduction in transfusion patients
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
We have been well guided in the "Good use of blood" during major surgery for many years, reaching a percentage of 4% of patients transfused after elective prosthetic operations. Valid patient blood management must provide for the possibility of limiting/zeroing the transfusion risk dependent on preoperative anemia, and the national guideline on PBM (Patient blood management) also underlines this Hypothesis and relevance
Detailed Description
We want to analyse patients from a diagnostic point of view (occult blood, diverticulitis, gastrorrhagia) and from the point of view of laboratory parameters (blood count, serum iron, transferrinemia, ferritinemia, transferrin saturation) in ordr to be able to suggest the best approach in preparation to the intervention. We want to evaluate the effectiveness of this approach, considering the proposed treatments (ferric carboxymaltose, chelated iron, folic acid, sideremil vita) and the transfusion result (or not) obtained
Investigators
Eligibility Criteria
Inclusion Criteria
- •Candidates for prosthetic surgery
- •Patients of both sexes over 40 years of age
- •Hemoglobin values \<12 g% for females and 13 g% for males
- •% transferrin saturation \< 10%
- •Willingness and ability to provide informed consent.
Exclusion Criteria
- •Patients with Mediterranean anemia
- •Patients with coagulation disorders
- •Patients who do not sign the consent form
- •Pregnant or breastfeeding women (self-declaration)
- •Minor aged
Outcomes
Primary Outcomes
Reduction in transfusion patients
Time Frame: 7 days post-surgery
Evaluate the reduction of transfusions in anemic patients treated with SideremilVita for 30 days before the intervention (group B experimental), compared to patients assuming SideremilVita at 15 days before surgery (control group A)